Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Shanghai Stock Exchange  >  Shanghai Fosun Pharmaceutical Group Co., Ltd.    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL GROUP CO.,

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Shanghai Fosun Pharmaceutical : VOLUNTARY ANNOUNCEMENT - THE PROGRESS OF THE PLAN FOR INCREASE IN SHAREHOLDING BY A CONTROLLING SHAREHOLDER(H SHARES)

share with twitter share with LinkedIn share with facebook
03/18/2020 | 10:06am EDT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

上 海 復 星 醫 藥( 集 團 )股 份 有 限 公 司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

VOLUNTARY ANNOUNCEMENT

THE PROGRESS OF THE PLAN FOR INCREASE IN SHAREHOLDING BY

A CONTROLLING SHAREHOLDER

This announcement is made on a voluntary basis by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'').

Reference is made to the announcement of the Company dated 19 September 2019 (the ''Announcement'') in relation to Shanghai Fosun High Technology (Group) Company Limited* (上海 復星高科技(集團)有限公司) (''Fosun High Tech''), the controlling shareholder of the Company, increased its shareholding in the Company (including A Shares and/or H Shares) and the Shareholding Increase Plan. Unless otherwise specified, capitalized terms used herein shall have the same meaning ascribed to them in the Announcement.

On 18 March 2020, the Company was notified by Fosun High Tech regarding the progress of the Shareholding Increase Plan, and the details of which are as follows:

  1. THE SHAREHOLDING INCREASE PLAN
    Given the confidence about the future prospects for development of the Company and the recognition of the Company's intrinsic value, Fosun High Tech intends to further increase its shareholding in the Company (including A Shares and/or H Shares) via the trading system of the Shanghai Stock Exchange (including the Shanghai-Hong Kong Stock Connect) by itself (and/or parties acting in concert with it) (the ''Shareholding Increase Party/Parties'') within the 12 months commencing from 19 September 2019 (inclusive), if and where appropriate, the cumulative total amount thereof shall not be less than RMB100 million and the increased shareholding percentage of Fosun High Tech and parties acting in concert with it in aggregate shall not exceed 2% of total issued shares of the Company as at 19 September 2019 (i.e 2,562,898,545 shares), and the aggregated number of shares in the Company to be acquired in the 12-month period shall not exceed 2% of the total number of issued shares in the Company. The detailed plan (including but not limited to the specific amount and number of shares of the shareholding increase) shall be

- 1 -

determined based on the market conditions and the Company's share price. In the event of any exentitlement or exdividend event in respect of the Company during the term of the Shareholdings Increase Plan, including but not limited to bonus issue, capital increase, issue of new shares or rights issue, the relative adjustment will be made to the Shareholding Increase Plan according to the change of share capital and will disclose the same in a timely manner accordingly. The funds required for the Shareholding Increase Plan are self-owned funds of the Shareholding Increase Parties.

  1. THE PROGRESS OF THE SHAREHOLDING INCREASE PLAN
    As at 18 March 2020, it has passed halfway period of the Shareholding Increase Plan. From 19 September 2019 to 18 March 2020, Fosun High Tech acquired through the Shanghai-Hong Kong Stock Connect trading system of the Shanghai Stock Exchange an aggregate number of 7,116,000 H Shares for an aggregate amount of approximately RMB148.9894 million, with the increased shareholding percentage of Fosun High Tech in aggregate represents approximately 0.28% of the total issued shares of the Company as at the date of this announcement (i.e 2,562,898,545, the same for below).

As at 18 March 2020 (after trading hours), Fosun High Tech held an aggregate of 977,644,790 shares of the Company (including 938,095,290 A Shares and 39,549,500 H Shares), representing approximately 38.15% of the total issued shares of the Company as at the date of this announcement.

  1. The Shareholding Increase Plan complies with the provisions of the Securities Law of the People's Republic of China and other applicable laws, regulations, department regulations and the relevant rules of Shanghai Stock Exchange and The Stock Exchange of Hong Kong Limited.

IV. Fosun High Tech undertakes that it and/or the parties acting in concert with it will not reduce its shareholding in the Company during the implementation of Shareholding Increase Plan and within the statutory restricted period.

- 2 -

  1. The Company will continue to pay attention to the situation regarding the shareholding increase in the Company by Shareholding Increase Party/Parties and make timely disclosure of the relevant information pursuant to the relevant regulations under the Rules Governing the Listing of Stocks on Shanghai Stock Exchange, Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, Measures for the Administration of the Takeover of Listed Companies and Guidelines for the Increase in Shareholdings by Shareholders of Listed Companies and Persons Acting in Concert with Such Shareholders of Shanghai Stock Exchange.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Qiyu

Chairman

Shanghai, the People's Republic of China

18 March 2020

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of the Company are Mr. Xu Xiaoliang and Ms. Mu Haining; and the independent non- executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

  • for identification purposes only

- 3 -

Disclaimer

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on 18 March 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 March 2020 15:02:19 UTC

share with twitter share with LinkedIn share with facebook
Latest news on SHANGHAI FOSUN PHARMACEUTI
07/30SHANGHAI FOSUN PHARMACEUTICAL GROUP : Ex-dividend day for final dividend
FA
07/27SHANGHAI FOSUN PHARMACEUTICAL : Says Covid-19 Vaccine in Phase 1 Clinical Trial
DJ
07/15SHANGHAI FOSUN PHARMACEUTICAL : China gives the go-ahead for human trials of Bio..
RE
07/15China gives the go-ahead for human trials of BioNTech's COVID vaccine candida..
RE
07/14SHANGHAI FOSUN PHARMACEUTICAL : Fosun Pharma Announces its Licensed COVID-19 Vac..
PU
07/12SHANGHAI FOSUN PHARMACEUTICAL : Plans to Raise $166 Million in India IPO
DJ
07/01BioNTech and Pfizer's COVID-19 vaccine shows potential in human trial
RE
06/29Temasek-led investor group in $250 million vaccine bet on Germany's BioNTech
RE
04/29Shanghai Fosun Pharmaceutical 1Q Net Fell 19% on Higher Research Expenses
DJ
03/30Shanghai Fosun Pharmaceutical 2019 Net Profit Rises 23%
DJ
More news
Financials
Sales 2020 32 396 M 4 643 M 4 643 M
Net income 2020 3 545 M 508 M 508 M
Net Debt 2020 13 549 M 1 942 M 1 942 M
P/E ratio 2020 44,6x
Yield 2020 0,66%
Capitalization 143 B 20 551 M 20 545 M
EV / Sales 2020 4,84x
EV / Sales 2021 4,13x
Nbr of Employees 31 370
Free-Float 62,3%
Chart SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical Group Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHANGHAI FOSUN PHARMACEUTI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 32,91 CNY
Last Close Price 62,23 CNY
Spread / Highest target -32,5%
Spread / Average Target -47,1%
Spread / Lowest Target -65,5%
EPS Revisions
Managers
NameTitle
Yi Fang Wu President, CEO & Executive Director
Qi Yu Chen Co-Chairman
Fang Yao Co-Chairman
Qian Ren Chairman-Supervisory Board
Xiao Hui Guan CFO, Chief Accountant Officer & Senior VP
Sector and Competitors